Paper1962075
Experimental leishmaniasis in humans: review.
Melby PC. Rev Infect Dis, 1991. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. Experimental leishmaniasis in humans: review. Papers, record 1962075. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1962075
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Insect Vectors | Major topic |
| Leishmania | Major topic |
| Leishmaniasis | Major topic |
| Psychodidae | Major topic |
| Animals | |
| Humans |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39095597 | Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis. | Nat Med | 2024 | https://conductscience.org/library/papers/39095597 | PubMed |
| 37805813 | Climate change and cutaneous leishmaniasis in the province of Ghardaïa in Algeria: A model-based approach to predict disease outbreaks. | Ann Saudi Med | 2023 | https://conductscience.org/library/papers/37805813 | PubMed |
| 36365010 | Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs. | Pathogens | 2022 | https://conductscience.org/library/papers/36365010 | PubMed |
| 34693027 | A clinical study to optimise a sand fly biting protocol for use in a controlled human infection model of cutaneous leishmaniasis (the FLYBITE study). | Wellcome Open Res | 2021 | https://conductscience.org/library/papers/34693027 | PubMed |
| 34664543 | Vaccines against leishmaniasis: using controlled human infection models to accelerate development. | Expert Rev Vaccines | 2021 | https://conductscience.org/library/papers/34664543 | PubMed |
| 34547025 | Human leishmaniasis vaccines: Use cases, target population and potential global demand. | PLoS Negl Trop Dis | 2021 | https://conductscience.org/library/papers/34547025 | PubMed |
| 29922288 | Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against Leishmania. | Front Immunol | 2018 | https://conductscience.org/library/papers/29922288 | PubMed |
| 26371247 | Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum. | J Immunol | 2015 | https://conductscience.org/library/papers/26371247 | PubMed |
| 25473946 | Chronic parasitic infection maintains high frequencies of short-lived Ly6C+CD4+ effector T cells that are required for protection against re-infection. | PLoS Pathog | 2014 | https://conductscience.org/library/papers/25473946 | PubMed |
| 23339200 | Restricted outbreak of American tegumentary leishmaniasis with high microfocal transmission. | Am J Trop Med Hyg | 2013 | https://conductscience.org/library/papers/23339200 | PubMed |
| 22292030 | Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters. | PLoS One | 2012 | https://conductscience.org/library/papers/22292030 | PubMed |
| 20207869 | Urban transmission of American cutaneous leishmaniasis in Argentina: spatial analysis study. | Am J Trop Med Hyg | 2010 | https://conductscience.org/library/papers/20207869 | PubMed |
| 18372625 | Transcriptional inhibition of interleukin-12 promoter activity in Leishmania spp.-infected macrophages. | J Parasitol | 2008 | https://conductscience.org/library/papers/18372625 | PubMed |
| 16517909 | First report of Leishmania infantum in French Guiana: canine visceral leishmaniasis imported from the Old World. | J Clin Microbiol | 2006 | https://conductscience.org/library/papers/16517909 | PubMed |
| 15730396 | Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response. | Clin Exp Immunol | 2005 | https://conductscience.org/library/papers/15730396 | PubMed |
| 14573692 | Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection. | Infect Immun | 2003 | https://conductscience.org/library/papers/14573692 | PubMed |
| 9782133 | Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. | J Exp Med | 1998 | https://conductscience.org/library/papers/9782133 | PubMed |
| 9367403 | Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis. | Clin Exp Immunol | 1997 | https://conductscience.org/library/papers/9367403 | PubMed |
| 8627163 | Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. | J Exp Med | 1996 | https://conductscience.org/library/papers/8627163 | PubMed |
| 7729921 | A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. | Infect Immun | 1995 | https://conductscience.org/library/papers/7729921 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1962075
GET https://conductscience.org/api/papers/v1/1962075/cited_by?page=2